A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 700
- Registration Number
- NCT06750094
- Locations
- π§πͺ
Universitair Ziekenhuis Leuven, Leuven, Belgium
π²π½Health Pharma Queretaro SA de CV, Queretaro, Mexico
πΈπͺSodersjukhuset, Stockholm, Sweden
Nipocalimab in Moderate to Severe Sjogren's Disease
- Conditions
- Sjogrens Syndrome
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06741969
- Locations
- π―π΅
Shinkenko Clinic, Naha, Japan
πΊπΈProvidence Saint John s Health Center, Santa Monica, California, United States
π§π·LMK Servicos Medicos S S, Porto Alegre, Brazil
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 365
- Registration Number
- NCT06667076
- Locations
- πΊπΈ
Southern Cancer Center, PC, Daphne, Alabama, United States
πΊπΈSutter Institute for Medical Research, Sacramento, California, United States
πΊπΈSansum Clinic, Santa Barbara, California, United States
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT06662786
- Locations
- πΊπΈ
St. Bernard's Medical Center, Jonesboro, Arkansas, United States
πΊπΈCBCC Global Research, Bakersfield, California, United States
πΊπΈLos Angeles Cancer Network, Glendale, California, United States
A Study of JNJ-89402638 for Metastatic Colorectal Cancer
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 170
- Registration Number
- NCT06663319
- Locations
- πͺπΈ
Hosp Univ Vall D Hebron, Barcelona, Spain
πΊπΈUniversity of Colorado Denver Anschultz Medical Campus, Aurora, Colorado, United States
πΊπΈFlorida Cancer Specialists, Sarasota, Florida, United States
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Conditions
- Crohns DiseaseColitis, UlcerativeArthritis, PsoriaticArthritis, Juvenile
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 196
- Registration Number
- NCT06663332
- Locations
- πΊπΈ
University of Utah, Salt Lake City, Utah, United States
π¨π³Changzhou No 2 Peoples Hospital, Changzhou, China
π―π΅Kobe University Hospital, Kobe, Japan
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06660563
- Locations
- πͺπΈ
Inst. Cat. Doncologia-H Duran I Reynals, L Hospitalet De Llobregat, Spain
π¦πΊConcord Hospital, Concord, Australia
π¦πΊSt Vincents Hospital Melbourne, Fitzroy, Australia
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06651229
- Locations
- πͺπΈ
Hosp Univ Fund Jimenez Diaz, Madrid, Spain
π¦πΊConcord Hospital, Concord, Australia
π¦πΊPeter MacCallum Cancer Centre, Melbourne, Australia
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Other: No intervention (Follow-Up assessment)
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT06646289
- Locations
- πΊπΈ
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
πΊπΈUniversity of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Geographic AtrophyMacular Degeneration
- Interventions
- Other: Sham Procedure
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 311
- Registration Number
- NCT06635148
- Locations
- πΊπΈ
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
π§πͺZiekenhuis Oost-Limburg, Genk, Belgium
π¨πΏAXON Clinical s.r.o., Prague, Czechia